Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Monte Rosa Therapeutics, Inc.GLUE · Entity 4828 | Director · President & CEO | July 16, 2026 | July 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Monte Rosa Therapeutics, Inc.
Report date July 16, 2026 · Filed July 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 585,038 |
Reported balance
After 2026-07-16 transaction · row 1
1 source rowRow 1 · 2026-07-16 · Sale · Disposed 9,500 · Balance 585,038 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.18 to $23.23, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.18 to $23.23, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 16, 2026 Filed Jul 17, 2026 20:05 UTC | Monte Rosa Therapeutics, Inc. GLUE · Entity 4828 | SaleCommon Stock | 9,500 | $23.18 | $220,218.55 |
DisclosureSEC source: 0001193125-26-307791 · ownership.xml · nonDerivative · entry 1 Warmuth Markus · CIK 0001855643 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 585,038 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.18 to $23.23, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 01, 2026 Filed Jun 2, 2026 20:05 UTC | Monte Rosa Therapeutics, Inc. GLUE · Entity 4828 | SaleCommon Stock | 468 | $19.73 | $9,231.86 |
DisclosureSEC source: 0001193125-26-253472 · ownership.xml · nonDerivative · entry 2 Warmuth Markus · CIK 0001855643 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 594,538 F1 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on May 14, 2025. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.69 to $19.77, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 01, 2026 Filed Jun 2, 2026 20:05 UTC | Monte Rosa Therapeutics, Inc. GLUE · Entity 4828 | SaleCommon Stock | 4,998 | $19.41 | $97,021.18 |
DisclosureSEC source: 0001193125-26-253472 · ownership.xml · nonDerivative · entry 1 Warmuth Markus · CIK 0001855643 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 595,006 F1 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on May 14, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.69 to $19.68, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 01, 2026 Filed May 5, 2026 20:05 UTC | Monte Rosa Therapeutics, Inc. GLUE · Entity 4828 | SaleCommon Stock | 5,467 | $18.92 | $103,446.57 |
DisclosureSEC source: 0001193125-26-206344 · ownership.xml · nonDerivative · entry 1 Warmuth Markus · CIK 0001855643 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 600,004 F1 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on May 14, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.67 to $19.38, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| April 14, 2026 Filed Apr 15, 2026 20:05 UTC | Monte Rosa Therapeutics, Inc. GLUE · Entity 4828 | SaleCommon Stock | 8,000 | $17.64 | $141,124.80 |
DisclosureSEC source: 0001193125-26-156981 · ownership.xml · nonDerivative · entry 1 Warmuth Markus · CIK 0001855643 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 605,471 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.64 to $17.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 21:50 UTC | Monte Rosa Therapeutics, Inc. GLUE · Entity 4828 | SaleCommon Stock | 5,466 | $17.92 | $97,974.22 |
DisclosureSEC source: 0001193125-26-091733 · ownership.xml · nonDerivative · entry 1 Warmuth Markus · CIK 0001855643 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 613,471 F1 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on May 14, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.50 to $18.46, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 07, 2026 Filed Jan 9, 2026 21:05 UTC | Monte Rosa Therapeutics, Inc. GLUE · Entity 4828 | SaleCommon Stock | 309 | $24.57 | $7,593.24 |
DisclosureSEC source: 0001193125-26-008902 · ownership.xml · nonDerivative · entry 3 Warmuth Markus · CIK 0001855643 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 618,937 F1 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on May 14, 2025. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.43 to $24.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 07, 2026 Filed Jan 9, 2026 21:05 UTC | Monte Rosa Therapeutics, Inc. GLUE · Entity 4828 | SaleCommon Stock | 1,450 | $23.88 | $34,620.49 |
DisclosureSEC source: 0001193125-26-008902 · ownership.xml · nonDerivative · entry 2 Warmuth Markus · CIK 0001855643 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 619,246 F1 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on May 14, 2025. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.43 to $24.41, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 07, 2026 Filed Jan 9, 2026 21:05 UTC | Monte Rosa Therapeutics, Inc. GLUE · Entity 4828 | SaleCommon Stock | 3,707 | $23.24 | $86,158.84 |
DisclosureSEC source: 0001193125-26-008902 · ownership.xml · nonDerivative · entry 1 Warmuth Markus · CIK 0001855643 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 620,696 F1 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on May 14, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.42 to $23.40, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 05, 2026 Filed Jan 5, 2026 21:04 UTC | Monte Rosa Therapeutics, Inc. GLUE · Entity 4828 | SaleCommon Stock | 10,135 | $15.17 | $153,747.95 |
DisclosureSEC source: 0001193125-26-002389 · ownership.xml · nonDerivative · entry 2 Warmuth Markus · CIK 0001855643 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 624,403 F2 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.17 to $15.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 02, 2026 Filed Jan 5, 2026 21:04 UTC | Monte Rosa Therapeutics, Inc. GLUE · Entity 4828 | GrantStock Option (Right to Buy) · Derivative | 406,000 | $0.00 Strike: $15.31 | $0.00 |
DisclosureSEC source: 0001193125-26-002389 · ownership.xml · derivative · entry 3 Warmuth Markus · CIK 0001855643 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 406,000 Underlying: Common Stock · 406,000 shares Expires 2036-01-01 F4 · derivative.exercise_date: 25% of this option shall vest and become exercisable on January 2, 2027, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| January 02, 2026 Filed Jan 5, 2026 21:04 UTC | Monte Rosa Therapeutics, Inc. GLUE · Entity 4828 | GrantCommon Stock | 90,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-002389 · ownership.xml · nonDerivative · entry 1 Warmuth Markus · CIK 0001855643 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 634,538 F1 · price: Represents restricted stock units ("RSUs") granted under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 25% of the RSUs shall vest on January 2, 2027, with the remainder vesting in 3 equal annual installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 21:15 UTC | Monte Rosa Therapeutics, Inc. GLUE · Entity 4828 | GrantStock Option (Right to Buy) · Derivative | 575,000 | $0.00 Strike: $7.11 | $0.00 |
DisclosureSEC source: 0000950170-25-002100 · ownership.xml · derivative · entry 2 Warmuth Markus · CIK 0001855643 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 575,000 Underlying: Common Stock · 575,000 shares Expires 2035-01-01 F2 · derivative.exercise_date: 25% of this option shall vest and become exercisable on January 1, 2026, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 21:15 UTC | Monte Rosa Therapeutics, Inc. GLUE · Entity 4828 | GrantCommon Stock | 128,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-002100 · ownership.xml · nonDerivative · entry 1 Warmuth Markus · CIK 0001855643 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 544,538 F1 · shares: Represents restricted stock units ("RSUs") granted under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 25% of the RSUs shall vest on January 1, 2026, with the remainder vesting in 3 equal annual installments thereafter, subject to the Reporting Person's continued service on each such vesting date. F1 · price: Represents restricted stock units ("RSUs") granted under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 25% of the RSUs shall vest on January 1, 2026, with the remainder vesting in 3 equal annual installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:15 UTC | Monte Rosa Therapeutics, Inc. GLUE · Entity 4828 | GrantStock Option (Right to Buy) · Derivative | 346,000 | $0.00 Strike: $5.71 | $0.00 |
DisclosureSEC source: 0001209191-24-000767 · doc4.xml · derivative · entry 1 Warmuth Markus · CIK 0001855643 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 346,000 Underlying: Common Stock · 346,000 shares Expires 2034-01-01 F1 · derivative.exercise_date: 25% of this option shall vest and become exercisable on January 1, 2025, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| January 03, 2023 Filed Jan 4, 2023 21:31 UTC | Monte Rosa Therapeutics, Inc. GLUE · Entity 4828 | GrantStock Option (Right to Buy) · Derivative | 472,000 | $0.00 Strike: $7.78 | $0.00 |
DisclosureSEC source: 0001209191-23-000956 · doc4.xml · derivative · entry 1 Warmuth Markus · CIK 0001855643 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 472,000 Underlying: Common Stock · 472,000 shares Expires 2033-01-02 F1 · derivative.exercise_date: 25% of this option shall vest and become exercisable on January 1, 2024, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| March 01, 2022 Filed Mar 2, 2022 23:26 UTC | Monte Rosa Therapeutics, Inc. GLUE · Entity 4828 | GrantStock Option (Right to Buy) · Derivative | 315,600 | $0.00 Strike: $13.41 | $0.00 |
DisclosureSEC source: 0000899243-22-008673 · doc4.xml · derivative · entry 1 Warmuth Markus · CIK 0001855643 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 315,600 Underlying: Common Stock · 315,600 shares Expires 2032-02-29 F1 · derivative.exercise_date: 25% of this option shall vest and become exercisable on January 1, 2023, with the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| June 23, 2021 Filed Jun 25, 2021 21:00 UTC | Monte Rosa Therapeutics, Inc. GLUE · Entity 4828 | GrantStock Option (Right to Buy) · Derivative | 141,623 | $0.00 Strike: $19.00 | $0.00 |
DisclosureSEC source: 0000899243-21-025976 · doc4.xml · derivative · entry 2 Warmuth Markus · CIK 0001855643 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,623 Underlying: Common Stock · 141,623 shares Expires 2031-06-22 F4 · derivative.exercise_date: 25% of this option shall vest and become exercisable on May 28, 2022, with the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| April 12, 2021 Filed Jun 25, 2021 21:00 UTC | Monte Rosa Therapeutics, Inc. GLUE · Entity 4828 | GrantStock Option (Right to Buy) · Derivative | 538,517 | $0.00 Strike: $6.14 | $0.00 |
DisclosureSEC source: 0000899243-21-025976 · doc4.xml · derivative · entry 1 Warmuth Markus · CIK 0001855643 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 538,517 Underlying: Common Stock · 538,517 shares Expires 2031-04-12 F1 · derivative.exercise_price: On June 17, 2021, the Issuer completed a one-for-3.5305 reverse stock split of the Issuer's Common Stock (the "Reverse Split"). This amount has been adjusted to give effect to the Reverse Split. F2 · kind: This transaction occurred prior to the Issuer's initial public offering, and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The securities covered by such transaction were previously included on the Reporting Person's Form 3. F1 · shares: On June 17, 2021, the Issuer completed a one-for-3.5305 reverse stock split of the Issuer's Common Stock (the "Reverse Split"). This amount has been adjusted to give effect to the Reverse Split. F3 · derivative.exercise_date: 25% of this option shall vest and become exercisable on April 9, 2022, with the remainder vesting in 36 substantially equal monthly installments thereafter. F1 · derivative.underlying_shares: On June 17, 2021, the Issuer completed a one-for-3.5305 reverse stock split of the Issuer's Common Stock (the "Reverse Split"). This amount has been adjusted to give effect to the Reverse Split. F1 · balance_after: On June 17, 2021, the Issuer completed a one-for-3.5305 reverse stock split of the Issuer's Common Stock (the "Reverse Split"). This amount has been adjusted to give effect to the Reverse Split. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.